Australian Health Journal Episode 1 Professor Gregg Suaning of University of Sydney talks about the bionic eye and entering the clinical trial phase.
#AustralianHealthJournal #BionicEye
You Might also like
-
CASE STUDY: Evolution in the medical device supply chain
For Cardinal Health, a global manufacturer and distributor of medical products, the process begins when products arrive in Australia and are cleared by customs before being stored at their Sydney warehouse. From here, they fulfil orders for various clients, including hospitals and wholesalers, supported by DHL’s logistics services.
-
AHJ S1E4: TAVI 10 Year Anniversary
2018 marks the 10 year anniversary of the TAVI device, short for the Transcatheter Aortic Valve Implantation. The TAVI system enables the replacement of a diseased aortic valve without open-heart surgery or surgical removal of the native valve.
This minimally invasive surgical option reduces operating time and allows for a shortened recovery period for patients.
AHJ met with the cardiologist teams in Melbourne’s Epworth and Alfred Hospital who have involved in implanting the device over the past 10 years.
Interviews:
- Associate Professor Tony Walton, Epworth Hospital, Director of Catheter Laboratory and Deputy Director of Cardiology – Alfred Health
- Associate Professor Ron Dick, Director of Cardiac Sciences – Epworth Healthcare
- Professor Stephen Duffy, Alfred Health
Post Views: 1,648 -
Cardinal Health brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.